Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01519869 · ClinicalTrials.gov registry record · Phase 2
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
A Phase 2 study, sponsored by Rachel Miller.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01519869: Completed Phase 2 study, sponsored by Rachel Miller.
NCT01519869 is a Phase 2 study that has completed, run by Rachel Miller. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01519869, a Phase 2 study, has completed, sponsored by Rachel Miller.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a prospective study to evaluate the hypothesis that platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy is associated with improved maximal surgical cytoreduction rates, comparable survival, decreased morbidity, and increased quality of life in patients with International Federation of Gynecologic Oncology stages IIIC and IV ovarian, primary peritoneal, or fallopian tube cancer when compared to historical controls and to evaluate the hypothesis that cancer induced inflammation is a predictor of poor prognosis and response to therapy in this group of ovarian cancer patients.
Primary Outcome
Percentage of patients that achieve maximal surgical debulking as defined by no gross residual disease following a Simon's 2-stage design.
Interventions
- DRUG neoadjuvant chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-03 |
| Est. Completion | 2019-10-11 |
| Phase | Phase 2 |
What the finished NCT01519869 record still lists
NCT01519869 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which neoadjuvant chemotherapy is the first listed.
NCT01519869 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01519869 about?
NCT01519869 is a clinical study titled "Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma". This is a prospective study to evaluate the hypothesis that platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy is associated with improved maximal surgical cytoreduction rates, comparable survival, decreased morbidity, and increa...
What is the current status of trial NCT01519869?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2012-03. Estimated completion is 2019-10-11.
What interventions are being tested in trial NCT01519869?
The interventions under investigation include: neoadjuvant chemotherapy (DRUG).
Who is sponsoring clinical trial NCT01519869?
This trial is sponsored by Rachel Miller, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01519869's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia